<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="924">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 27, 2015</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01367964</url>
  </required_header>
  <id_info>
    <org_study_id>2011-14518</org_study_id>
    <nct_id>NCT01367964</nct_id>
  </id_info>
  <brief_title>Prevention of West Syndrome With Low-dose Adrenocorticotropin Hormone (ACTH)</brief_title>
  <acronym>PREVENT-WS</acronym>
  <official_title>Early Treatment of Infants at High Risk of Developing West Syndrome With Low-dose Adrenocorticotropin Hormone (ACTH)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ann &amp; Robert H Lurie Children's Hospital of Chicago</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Thrasher Research Fund</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Ann &amp; Robert H Lurie Children's Hospital of Chicago</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      West syndrome (WS) is a specific type of epilepsy (or seizure disorder) that has three
      features: infantile spasms (type of seizure), loss of milestones, and a specific pattern on
      electroencephalogram (EEG or brain wave test) called hypsarhythmia. The purpose of this
      study is to detect pre-hypsarhythmia in infants at high-risk for WS and determine whether
      treatment with ACTH will prevent WS.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Hypothesis: Preemptive ACTH will halt the evolution of hypsarhythmia and improve the EEG
      patterns in infants with pre-hypsarhythmic EEG.

      Aim. To determine whether a low dose ACTH improves EEG, we will repeat EEG one month after a
      2 week course of daily ACTH.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2011</start_date>
  <primary_completion_date type="Anticipated">June 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>Evidence for improvement in the EEG one month following initiation of the 2 week course of low-dose ACTH.</measure>
    <time_frame>1 month</time_frame>
    <safety_issue>No</safety_issue>
    <description>If pre-hypsarhythmia (Type 3) is detected, ACTH treatment is given for 2 weeks and an EEG is performed one month later. Primary outcome is improvement in EEG (as defined by assigned type).</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">28</enrollment>
  <condition>West Syndrome</condition>
  <arm_group>
    <arm_group_label>ACTH treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Infants with a Type 3 EEG (pre-hypsarhythmia) will be treated with ACTH for 2 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>adrenocorticotropin hormone</intervention_name>
    <description>ACTH 16 units intramuscular injection once daily for 2 weeks</description>
    <arm_group_label>ACTH treatment</arm_group_label>
    <other_name>H.P. ActharÂ® Gel (repository corticotropin injection)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Infants with pre-hypsarhythmia (Type 3 EEG) between 2 months to 12 months of age.

        Exclusion criteria:

          -  Infants with any of the following diagnoses:

          -  A previous history of infantile spasms;

          -  Known inborn error of metabolism;

          -  Other symptomatic epileptic encephalopathy (e.g. Ohtahara syndrome).
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>2 Months</minimum_age>
    <maximum_age>12 Months</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John J. Millichap, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ann &amp; Robert H. Lurie Children's Hospital of Chicago and Northwestern University Feinberg School of Medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sookyong Koh, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ann &amp; Robert H. Lurie Children's Hospital of Chicago and Northwestern University Feinberg School of Medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Doulgas R Nordli, Jr, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ann &amp; Robert H. Lurie Children's Hospital of Chicago and Northwestern University Feinberg School of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>John J. Millichap, MD</last_name>
    <phone>312-227-3540</phone>
    <email>jmillichap@luriechildrens.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sookyong Koh, MD, PhD</last_name>
    <phone>312-227-3540</phone>
    <email>skoh@luriechildrens.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Ann &amp; Robert H. Lurie Children's Hospital of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John J Millichap, MD</last_name>
      <phone>312-227-3540</phone>
      <email>jmillichap@luriechildrens.org</email>
    </contact>
    <contact_backup>
      <last_name>Sookyong Koh, MD, PhD</last_name>
      <phone>312-227-3540</phone>
      <email>skoh@luriechildrens.org</email>
    </contact_backup>
    <investigator>
      <last_name>John J Millichap, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sookyong Koh, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>SOREL L, DUSAUCY-BAULOYE A. [Findings in 21 cases of Gibbs' hypsarrhythmia; spectacular effectiveness of ACTH]. Acta Neurol Psychiatr Belg. 1958 Feb;58(2):130-41. French.</citation>
    <PMID>13532578</PMID>
  </reference>
  <reference>
    <citation>Okumura A, Watanabe K. Clinico-electrical evolution in pre-hypsarrhythmic stage: towards prediction and prevention of West syndrome. Brain Dev. 2001 Nov;23(7):482-7.</citation>
    <PMID>11701242</PMID>
  </reference>
  <reference>
    <citation>Suzuki M, Okumura A, Watanabe K, Negoro T, Hayakawa F, Kato T, Itomi K, Kubota T, Maruyama K. The predictive value of electroencephalogram during early infancy for later development of West syndrome in infants with cystic periventricular leukomalacia. Epilepsia. 2003 Mar;44(3):443-6.</citation>
    <PMID>12614401</PMID>
  </reference>
  <reference>
    <citation>Philippi H, Wohlrab G, Bettendorf U, Borusiak P, Kluger G, Strobl K, Bast T. Electroencephalographic evolution of hypsarrhythmia: toward an early treatment option. Epilepsia. 2008 Nov;49(11):1859-64. doi: 10.1111/j.1528-1167.2008.01715.x. Epub 2008 Jul 9.</citation>
    <PMID>18631366</PMID>
  </reference>
  <reference>
    <citation>Watanabe K, Iwase K, Hara K. The evolution of EEG features in infantile spasms: a prospective study. Dev Med Child Neurol. 1973 Oct;15(5):584-96.</citation>
    <PMID>4358106</PMID>
  </reference>
  <reference>
    <citation>Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials. 1989 Mar;10(1):1-10.</citation>
    <PMID>2702835</PMID>
  </reference>
  <verification_date>February 2015</verification_date>
  <lastchanged_date>February 3, 2015</lastchanged_date>
  <firstreceived_date>June 3, 2011</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ann &amp; Robert H Lurie Children's Hospital of Chicago</investigator_affiliation>
    <investigator_full_name>John J Millichap, MD</investigator_full_name>
    <investigator_title>Attending Physician, Division of Neurology</investigator_title>
  </responsible_party>
  <keyword>Hypsarrhythmia</keyword>
  <keyword>Spasms, Infantile</keyword>
  <keyword>West Syndrome</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Spasms, Infantile</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Adrenocorticotropic Hormone</mesh_term>
    <mesh_term>Beta-Endorphin</mesh_term>
    <mesh_term>Hormones</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
